The Oncology Institute, Inc. (STLN) Q3 2026 earnings results
The Oncology Institute, Inc. (STLN) reported Q3 2026 results on Nov 5, 2026, 4:57:14 PM ET: GAAP EPS -$0.13 vs. -$0.05 expected (miss by $0.08); revenue $169.77M vs. $168.69M expected (beat by 0.6%). Outlook: The company affirmed its full-year 2026 guidance for revenue, gross profit, adjusted EBITDA, and free cash flow.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (GAAP, diluted) | -$0.13 | -$0.05 | Miss by $0.08 |
| Revenue | $169.77M | $168.69M | Beat by 0.6% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 5, 2026, 4:57:14 PM ET. Nexqual published them 30 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 24.3% from $136.56M; GAAP diluted EPS was -$0.13 vs. -$0.14 (+7.1%).
Stock reaction
The results came out after the market closed. STLN closed at $3.62 on November 6, 2026, down 46.0% from its $6.70 close on November 5, 2026 before the results. Latest: $4.10 as of 11:40 AM ET, −38.8% since the pre-release close.
Questions and answers
Did The Oncology Institute, Inc. beat earnings expectations?
No. The Oncology Institute, Inc. reported GAAP EPS of -$0.13 against an average analyst estimate of -$0.05 (miss by $0.08), and revenue of $169.77M against $168.69M expected (beat by 0.6%).
What were The Oncology Institute, Inc.'s Q3 2026 earnings and revenue?
GAAP diluted EPS of -$0.13 and revenue of $169.77M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 24.3% from $136.56M; GAAP diluted EPS was -$0.13 vs. -$0.14 (+7.1%).
When did The Oncology Institute, Inc. report Q3 2026 earnings?
Nov 5, 2026, 4:57:14 PM ET, in an SEC 8-K filing (Item 2.02).
How did STLN stock react to the earnings?
The results came out after the market closed. STLN closed at $3.62 on November 6, 2026, down 46.0% from its $6.70 close on November 5, 2026 before the results. Latest: $4.10 as of 11:40 AM ET, −38.8% since the pre-release close.
What did The Oncology Institute, Inc. say about its outlook?
The company affirmed its full-year 2026 guidance for revenue, gross profit, adjusted EBITDA, and free cash flow.
More on STLN
STLN stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 5, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 10, 2026 at 16:40 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 10, 2026 at 16:40 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt